Combining benefits in glaucoma

Article

Combining benefits in glaucoma

Attacking glaucoma with a combination treatment strategy achieves a significant reduction in intraocular pressure in patients unresponsive to monotherapy, according to a study presented at the annual meeting of ARVO in Florida.

Preliminary results of the EXACCT study [Evaluation of Xalatan (latanoprost) and Cosopt (dorzolamide hydrochloride/timolol maleate)] demonstrated IOP control in 92.6% of those patients who were unresponsive to, or were uncontrolled, with latanoprost, when treated with the combination treatment, Cosopt alone, or when the investigational agent was added to latanoprost therapy.

The multicentre, open-label, 12-week EXACCT study enrolled 343 patients across Canada. The preliminary study results related to 243 participants; 196 of the patients had either open-angle glaucoma or ocular hypertension and received Cosopt in addition to latanoprost after a four-week course of latanoprost monotherapy failed to control IOP. The remaining 47 patents were completely unresponsive to latanoprost and hence were switched to Cosopt therapy.

Mark Lesk, MD, EXACCT study co-author and vision health researcher with the Guy-Bernier Research Centre at Montreal's Maisonneuve-Rosemont Hospital, University of Montreal, Canada, noted a 28.3% (15.78 mmHg vs. 22.34 mmHg) reduction of IOP from latanoprost baseline, when patients received both latanoprost and Cosopt. In latanoprost unresponsive patients, Cosopt alone achieved an average reduction of 24.4% in IOP (17.29 mmHg vs. 23.14 mmHg). According to Lesk, the overall treatment strategy was generally well tolerated with the majority (77%) of adverse events being mild in nature.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.